Cytiva & Pall: Chromotography, cell culture and SUS to benefit from $1.5bn
The investment will expand manufacturing capacity for life sciences products at thirteen Danaher Corporation sites run by Cytiva and Pall to meet customer demand. The $1.5 billion investment is in addition to Cytiva’s $500 million growth strategy that was announced in September 2020 and an ...
Xell AG is only Sartorius’s second acquisition this year despite CEO Joachim Kreuzburg saying his firm look at numerous &A activities each ...
Resilience will acquire Bluebird’s North Carolina lentiviral vector manufacturing facility for $110 million, kickstarting an alliance to drive ...
Emergent took a $54 million hit from remediation efforts and inventory write-downs at its Bayview plant and saw a $108 million reduction in its C ...
Repligen will lease a plant in Hopkington, Massachusetts and build a facility in Waterford, Ireland as part of capacity growth plans.
Repligen ...
Recent Tweets
-
RT @BioProcessIntl: Editor @Dan5tanton speaks with Sam Machour from Samsung Biologics about the rapid response by both his company and… https://t.co/tAH5P3kAeb
1 month ago
-
RT @Dan5tanton: In the latest example of pandemic-related collaboration, @Novartis is prepping to make the drug substance for Roche… https://t.co/IpIbSP7F1c
4 months ago
-
RT @Dan5tanton: As part of a “difficult decision” to halt its biosimilars programs in China, Pfizer is offloading its single-use bi… https://t.co/vsE7WAknKd
5 months ago
-
RT @Dan5tanton: Thermo Fisher’s $600 million CAPEX has got the trade press salivating. But similar statements, expansions underway,… https://t.co/5xHNdfJwRw
5 months ago
